Effect of omega 3 on serum albumin levels, lipid profile and urea and creatinine profile in patients admitted to the Intensive care unit

Effect of fish oil supplementation (omega 3) on serum albumin levels, lipid profile and urea and creatinine profile in patients admitted to the Intensive care unit

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180210038685N2

Enrollment

106

Registered

2019-05-30

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoalbuminemia. Deficiency of multiple nutrient elements

Interventions

Intervention 1: Intervention group: Soft gel capsule of 1000 mg of fish oil (Omega-3) ,Prepared from the Minoo Pharmaceutical Company, through the nasogastric tube , five times daily for 14 days Will

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Hospitalized patients in intensive care unit Age range is 50 - 85 years old They are fed with a solution prepared in the hospital and through a nasogastric tube Their serum albumin levels are less than 2.5 g / dL Be hospitalized for at least 14 days.

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Taking medications such as corticosteroids, tamoxifen, methotrexate, aspirin and warfarin, and any anticoagulants, those with blood disorders People with poor immune system or who take immunosuppressive drugs People with diabetes and high and uncontrolled blood pressure.

Design outcomes

Primary

Measure	Time frame
Albumin. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Urea. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Creatinine. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;High-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Triglycerides. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Cholesterol. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Very low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.	—

Measure

Time frame

Albumin. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Urea. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Creatinine. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;High-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Triglycerides. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Cholesterol. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.;Very low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Enzymatic assay by kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Alboativi

Ahvaz University of Medical Sciences

kishsami29@gmail.com+98 61 3333 3477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026